Fermer le menu


Member of Lyonbiopole


GAOMA Therapeutics is an early-stage biotech based in France, with an expertise in the development of bioactive lipids derivatives.

The company’s first asset, GAO-3-02, is a first-in-class derivative of an endogenous lipid named synaptamide, that we designed with a biomimetic approach. The drug-candidate acts on neuroplasticity and inflammation, with epilepsy and cognitive disorders as initial targeted indications.


Strategic application domain: Human Medicine

Application market: Neurology & Mental Health Disorders, Pain, Pediatrics

Type of activity: Therapeutics, Pharma or Biotech

Technologies: Small Molecules

Created on feb. 26th, 2019 - 5 employees



Institut Des Epilepsies Europe - IDEE, 59 Boulevard Pinel 69500 Bron



Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.